he Board of Pharmacy distributed its monthly News Roundup for November. This issue includes important information related to vaccines, albuterol and epinephrine standing orders for schools, the California Medication Error Reporting (CAMER), drug theft/drug loss online portal and PIC training webinar. 

Also in California, the November 2025 issue of the Board of Pharmacy's newsletter, The Script, is now published online. The November 2025 newsletter includes information on: 

  • New Laws 
  • Regulations 
  • Immunization Alert 
  • Importance of Patient Consent Forms 
  • CAMER 
  • Inspection Results 
  • Citations Issued 
  • Technology the Pharmacist's Role in Medication Safety 
  • Standing Orders for Schools Regarding Albuterol and Epinephrine 
  • Well-Being Index 

Also in California, the Board of Pharmacy sent the following reminder to licensees.  

Business and Professions Code (BPC) section 4113.1 establishes requirements for a community pharmacy to report medication errors known as CAMER to an entity approved by the Board. The statute requiring medication error reporting by community pharmacies can be viewed at BPC section 4113.1. The Board approved the Institute for Safe Medication Practices (ISMP), an ECRI Company, as the entity to receive and review medication error reports under BPC section 4113.1. Information regarding CAMER registration can be found at https://mederrors.ismp.org/.  

The Board reminds community pharmacy licensees that medication errors that occur on or after September 1, 2025, must be reported to the CAMER system consistent with legal requirements established.  

Also in California, the Department of Health Care Service posted the following on the Medi-Cal Rx Web Portal: 

 

Finally in California, pursuant to the announced pharmacy benefit policy changes effective January 1, 2026, the Department of Health Care Services (DHCS) mailed letters to Medi-Cal members to notify them of two upcoming changes:  

  • All Medi-Cal members received a letter concerning the exclusion of coverage for GLP-1 medications for weight-loss indications. 
  • Impacted Medi-Cal members received a letter concerning the need for prior authorization (PA) approval for select medications previously filled without a PA request. 

 Both letters provide members with information about the policy change and guidance concerning potential actions the member may take. 

Questions may be submitted to the Pharmacy Benefits Division at Medi-Cal.PharmacyBenefits@dhcs.ca.gov or to the Medi-Cal Rx Education and Outreach team at Medicalrxeducationoutreach@primetherapeutics.com 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.